🏭 The collaboration will strengthen Samsung’s manufacturing capabilities at its new ADC facility, enhancing both companies’ market competitiveness.
💡 This partnership aims to accelerate ADC treatments for patients and solid tumor therapies, showcasing commitment to high-quality biopharmaceuticals.
Introduction:
This article discusses the extension of a collaborative agreement between Samsung Biologics and LigaChem Biosciences (LCB) to enhance the development and manufacturing of antibody-drug conjugates (ADCs), a promising class of therapeutics for solid tumors.
- Samsung Biologics has expanded its collaboration with LigaChem to support ADC services at its new dedicated ADC facility.
- The partnership aims to enhance capabilities across all stages of ADC development and manufacturing, focusing on delivering high-quality therapeutics.
- John Rim, CEO of Samsung Biologics, emphasizes the commitment to provide safe and effective drugs to patients through this collaboration.
- Yong-Zu Kim, CEO of LCB, views this partnership as a crucial step in strengthening the supply chain for high-quality ADCs and improving competitiveness in the global market.
- Samsung Biologics is investing in ADC linker technologies, protein engineering, and expanding its manufacturing capacity, which will be bolstered further by the upcoming operational Plant 5.
Conclusion:
The extended collaboration between Samsung Biologics and LigaChem represents a significant advancement in ADC development, with mutual benefits anticipated for both companies. This initiative is projected to enhance the therapeutic landscape for patients with solid tumors and underlines the growing importance of ADCs in biopharmaceutical innovation and manufacturing.
